Factors Associated with Ischemic Stroke on Therapeutic Anticoagulation in Patients with Nonvalvular Atrial Fibrillation
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: In this study, we investigated the stroke mechanism and the factors associatedwith ischemic stroke in patients with nonvalvular atrial fibrillation (NVAF) who were on optimal oral anticoagulation with warfarin. Materials and Methods: This was a multicenter case-control study. The cases were consecutive patients with NVAF who developed cerebral infarction or transient ischemic attack (TIA) while on warfarin therapy with an international normalized ratio (INR) ≥2 between January2007 and December 2011. The controls were patients with NVAF without ischemicstroke who were on warfarin therapy for more than 1 year with a mean INR ≥2 during the same time period. We also determined etiologic mechanisms of stroke in cases. Results: Among 3569 consecutive patients with cerebral infarction or TIA who had NVAF, 55 (1.5%) patients had INR ≥2 at admission. The most common stroke mechanism was cardioembolism (76.0%). Multivariate analysis demonstrated that smoking and history of previous ischemic stroke were independently associated with cases. High CHADS2 score (≥3) or CHA2DS2-VASc score (≥5), in particular, with previous ischemic stroke along with ≥1 point of other components of CHADS2 score or ≥3 points of other components of CHA2DS2-VASc score was a significant predictor for development of ischemic stroke. Conclusion: NVAF patients with high CHADS2/CHA2DS2-VASc scores and a previous ischemic stroke or smoking history are at high risk of stroke despite optimal warfarin treatment. Some other measures to reduce the risk of stroke would be necessary in those specific groups of patients.
Abstract
Purpose: In this study, we investigated the stroke mechanism and the factors associatedwith ischemic stroke in patients with nonvalvular atrial fibrillation (NVAF) who were on optimal oral anticoagulation with warfarin. Materials and Methods: This was a multicenter case-control study. The cases were consecutive patients with NVAF who developed cerebral infarction or transient ischemic attack (TIA) while on warfarin therapy with an international normalized ratio (INR) ≥2 between January2007 and December 2011. The controls were patients with NVAF without ischemicstroke who were on warfarin therapy for more than 1 year with a mean INR ≥2 during the same time period. We also determined etiologic mechanisms of stroke in cases. Results: Among 3569 consecutive patients with cerebral infarction or TIA who had NVAF, 55 (1.5%) patients had INR ≥2 at admission. The most common stroke mechanism was cardioembolism (76.0%). Multivariate analysis demonstrated that smoking and history of previous ischemic stroke were independently associated with cases. High CHADS2 score (≥3) or CHA2DS2-VASc score (≥5), in particular, with previous ischemic stroke along with ≥1 point of other components of CHADS2 score or ≥3 points of other components of CHA2DS2-VASc score was a significant predictor for development of ischemic stroke. Conclusion: NVAF patients with high CHADS2/CHA2DS2-VASc scores and a previous ischemic stroke or smoking history are at high risk of stroke despite optimal warfarin treatment. Some other measures to reduce the risk of stroke would be necessary in those specific groups of patients.
참고문헌 (28)
- Cardiogenic brain embolism, "Cerebral Embolism Task Force", Arch Neurol, 43, pp.71~84 (1986)
- Han SW, "Frequency and significance of cardiac sources of embolism in the TOAST classification", Cerebrovasc Dis, 24, pp.463~468 (2007)
- Wann LS, "2011 ACCF", AHA, American Heart Association Task Force on Practice Guidelines, pp.J Am Coll Cardiol, 2011[DOI]
- Furie KL, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association", american stroke association, 2011, pp.42, 227~276
- European Stroke Organisation (ESO) Executive Committee, "Guidelines for management of ischaemic stroke and transient ischaemic attack 2008", Cerebrovasc Dis, 25, pp.457~507 (2008)
- Paciaroni M, "Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention", Atherosclerosis, 212, pp.564~566 (2010)
- Gage BF, "Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation", JAMA, 285, pp.2864~2870 (2001)
- Lip GY, "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation", Chest, 137, pp.263~272 (2010)
- Kim YD, "Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation", Stroke, 42, pp.930~934 (2011)
- Melkas S, "Small-vessel disease relates to poor poststroke survival in a 12-year follow-up", Neurology, 76, pp.734~739 (2011)
- Rosendaal FR, "A method to determine the optimal intensity of oral anticoagulant therapy", Thromb Haemost, 69, pp.236~239 (1993)
- Adams HP Jr, "Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment", Stroke, 24, pp.35~41 (1993)
- Agarwal S, "Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis", Arch Intern Med, 172, pp.623~631 (2012)
- Nakamura A, "Intensity of anticoagulation and clinical outcomes in acute cardioembolic stroke : the Fukuoka Stroke Registry", Stroke, 44, pp.3239~3242 (2013)
- Kanter MC, "Carotid stenosis in patients with atrial fibrillation. Prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study", Arch Intern Med, 154, pp.1372~1377 (1994)
- Evans A, "Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?", Stroke, 32, pp.2828~2832 (2001)
- Fuster V, "2011 ACCF", AHA, AHA, pp.ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation, American Heart Association Task Force on practice guidelines[DOI]
- Ntaios G, "Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials", Stroke, 43, pp.3298~3304 (2012)
- Albertsen IE, "Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis", Stroke, 44, pp.1329~1336 (2013)
- Chiang CE, "Stroke prevention in atrial fibrillation: an Asian perspective", Thromb Haemost, 111, pp.789~797 (2014)
- Reddy VY, "Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial", Circulation, 127, pp.720~729 (2013)
- Lip GY, "Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort", Stroke, 41, pp.2731~2738 (2010)
- Novello P, "Ischemic stroke and atrial fibrillation. A clinical study", Ital J Neurol Sci, 14, pp.571~576 (1993)
- "Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials", Arch Intern Med, 154, pp.1449~1457 (1994)
- Watson T, "Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited", Lance, 373, pp.155~166 (2009)
- Johnson CM, "Hypercoagulable states: a review", Vasc Endovascular Surg, 39, pp.123~133 (2005)
- Tracy RP, "Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects", Arterioscler Thromb Vasc Biol, 17, pp.2167~2176 (1997)
- 오순민, "Development and Application of Chronic Disease Risk Prediction Models", Yonsei Medical Journal, 55(4), pp.853~860 (2014), 연세대학교의과대학[DOI]